CJ CheilJedang steps up biotech drive with PHA mass production Korean food and bio company begins mass production of biodegradable plastic
Translated by Ryu Ho-joung 공개 2022-05-16 08:05:48
이 기사는 2022년 05월 13일 08:00 thebell 에 표출된 기사입니다.
South Korea’s CJ CheilJedang started mass production of polyhydroxyalkanoate (PHA) biodegradable plastic at its plant in Pasuruan, Indonesia, the company said on Wednesday, a move in line with its drive to expand its biotech business for future growth.The plant can produce 5,000 metric tons of amorphous PHA a year. PHA is a natural polyester polymer that can be totally decomposed in the ocean and soil and thus is a viable alternative to petroleum-based plastic.
CJ CheilJedang has proprietary amorphous PHA technology, which is used as a modifier to other polymers to improve processing characteristics. It is the only company in the world that succeeded in mass-producing amorphous PHA.
CJ CheilJedang is also building a facility that will produce semi-crystalline PHA, which are used to make things like medical supplies, fibers and straws. The company plans to increase its PHA production capacity to 65,000 metric tons a year by 2025.
“Our ability to produce both amorphous PHA and semi-crystalline PHA gives us an edge over competitors in expanding the business,” an official at CJ CheilJedang said. Other PHA producers like US-based Danimer Scientific and Japan’s Kaneka Corporation make semi-crystalline PHA only.
CJ CheilJedang secured contracts to supply over 5,000 metric tons of amorphous PHA to global companies even before the mass production began.
The global biodegradable plastic market is expected to grow to 16 trillion won ($12.5 billion) in 2025 from about 5 trillion won last year amid tightened environmental rules, especially in developed countries, that are accelerating a shift to environmentally friendly packaging.
Biopharmaceutical ambitions
In July last year, CJ CheilJedang acquired bioinformatics company ChunLab, now renamed CJ Bioscience, for about 100 billion won in a deal to expand its business to include biopharmaceutical products.
CJ Bioscience is still in the red and is expected to take time to turn profitable. CJ CheilJedang recorded 60.9 billion won in goodwill related to CJ Bioscience at the end of 2021, suggesting it believes in the biopharmaceutical company’s growth potential.
CJ CheilJedang also purchased a 76% stake in Batavia Biosciences, a Dutch biotechnology contract manufacturer, for 267.7 billion won in November last year.
“We will continue to make efforts and investment in R&D to strengthen the competitiveness of our biotech business and improve profitability,” the CJ CheilJedang official said. (Reporting by Nu-ri Moon)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [ICTK road to IPO]경쟁자 없는 '차세대 보안칩', 2000억 후반 밸류 '정조준'
- CG인바이츠, 화일약품 지원 축소 11년 동행 '선긋기'
- [K-바이오 클러스터 기행|대전]대전 바이오 구심점, 20년 역사 바이오헬스케어협회
- 코인원, 이용규 CPO 영입…신규 서비스 출시 속도
- [코스닥 코스메틱 리뉴얼]마스크팩 잘나가던 지피클럽, 색조화장 '코디 인수'
- [K-배터리 밸류업 리포트]'오너 경영체제' 원준, 승계작업 '언제쯤'
- [thebell note]제약바이오는 다이어트 중
- [바이오텍 유증·메자닌 승부수]브릿지바이오, 유무상증자에 '대표 지분 블록딜' 왜?
- [제일약품의 온코닉테라퓨틱스 첫 '신약']성장성·사업성 갖춘 IPO 기대주 '밸류업' 이유 더 있다
- [코스닥 리빌딩 리포트]'조달 지연' 비투엔, 불성실공시법인 지정 가능성은